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Abstract
Introduction:  A  high  incidence  of  postoperative  nausea  and  vomiting  has  been  observed  in
patients  undergoing  laparoscopic  cholecystectomy  (20--40%).  This  causes  an  increase  in  patient
discomfort,  a  delay  in  recovery,  and an  increase  in hospital  stay.
Objective:  Compare  the  efficacy  of  ondansetron  plus  metoclopramide  and  ondansetron  alone
in the control  of  postoperative  nausea  and  vomiting  in patients  undergoing  laparoscopic  chole-
cystectomy.
Material  and methods:  A  comparative,  prospective,  experimental,  longitudinal  double  blind
study was  performed  with  30  patients  programmed  for  laparoscopic  cholecystectomy.  The  Apfel
score was  applied  postoperatively.  Patients  were  divided  into  two  groups  with  15  participants.
Metoclopramide  10  mg  and  ondansetron  4 mg  were  administered  in  the  first  Group  (A),  and
ondansetron  4 mg  in  the second  Group  (B),  after  induction  of  anesthesia.  Nausea  and  vomiting
were evaluated  for  24  h postoperatively  using  a  Likert  scale.
Results:  Of  the  patients  who  presented  nausea,  the  condition  was  mild.  The  patient  who  pre-
sented vomiting,  vomited  only  once.  Neither  group  required  rescue  drugs.  Regarding  the  Apfel
score, there  was  no  correlation  between  the  percentage  of  stratified  risk  and  the  patients  who
presented  postoperative  nausea  and  vomiting.
Conclusions:  No statistically  significant  difference  was  observed  between  ondansetron  plus
metoclopramide  and  ondansetron  alone  in patients  subjected  to  laparoscopic  cholecystectomy.
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Introduction
Laparoscopic  cholecystectomy  is the golden  choice  in the
treatment  of  gallbladder  disease  and  has  been  proven to
be  better  in  the cost-effectiveness-efficiency  relation  when
compared  to  open  surgery.1,2
Out  of 100 laparoscopic  cholecystectomies  performed,
between  20  and  42%  present  a  complication,  postoperative
nausea  and  vomiting  (PONV),  which  delays  the patients’  dis-
charge.  It  translates  into  greater  postoperative  discomfort
and  distress  for  patients,  on  top  of  the fact that  they  usu-
ally  remain  50%  longer  in the recovery  room,  thus  altering
the  patient  flow  of  the  hospital  and  increasing  internment
costs.  PONV  can also  increase  suture  tension  and  the  risk
of  pulmonary  aspiration,  which  could  lead  to  pneumonia  or
pneumonitis  and  the increase  of  intracranial  pressure.  Its
etiology  includes  dehydration  by  fasting,  the  use  of  opioids,
nitrous  oxide,  inhaled  anesthetics  in  general  anesthesia,
pneumoperitoneum,  CO2 and  handling  of  the parietal  peri-
toneum  with  vagal  stimulation.  The  risk  of  PONV  ought  to
be  stratified  preoperatively  and  reduced,  adapting  anes-
thetic  techniques  or  using  the available  pharmacological
resources.3--5
There  are  different  PONV  predictive  models  that,  if
applied,  can  help  prevent  its  presence.  When  ranked  by  sen-
sitivity,  the Apfel  score  is  the most used in the reviewed
bibliography  (see Table  1).6
The  different  vomit  stimuli  are related  to  the dopamin-
ergic,  histaminergic,  serotoninergic,  muscarinic  and  opioid
receptors  located  in the central  pathways  (reticular
formation  of  the medulla)  and  peripheral  pathways  (gas-
trointestinal  system),  thus  their  blockage  is  a  mechanism
of  antiemetic  medications.
There  are  different  antiemetic  families;  H1  antihis-
tamines,  anticholinergic,  steroids,  phenothiazine,  buty-
rophenones,  dopamine  antagonists  and 5-HT3 receptor
antagonists.  These  medications  are currently  being  uti-
lized  in  an  isolated  or  combined  form.  Metoclopramide,
an  antiemetic  from  the  benzamide  group  with  anti-
dopaminergic  and  central  and peripheral  antiemetics,  acts
in  the  upper  gastrointestinal  tracts  for  2  h  (10--20 mg for
every  70  kg on  average  in adults).  Ondansetron  is  an  antag-
onist  of  the  serotonin  receptor  (5-HT3).  It  has been  used
for  some  years  to  control  nausea  and  vomiting  induced  by
Table  1  Apfel  risk assessment  scale  for  nausea  and
vomiting.
Risk  factors  Points  Risk
Female  1 Low  risk  (0--1
points)  10--20%
Non-smoker  1 Moderate  risk  (2
points)  40%
Previous  history  of
postoperative  vomiting
and/or  motion  sickness
1  High  risk  (3--4
points)  60--80%
Use  of  postoperative  opioids  1
I. Bel Marcoval. Estratificación del riesgo, profilaxis y
tratamiento de las náuseas y vómitos postoperatorios. Rev. Esp.
Anestesiol. Reanim. 2006; 53: 301--311.
chemotherapy  and  radiotherapy.  It  has central  and  periph-
eral effects.  Doses  of  4  mg peak  plasmatic  concentrations
are  reached  in  approximately  7--11 min depending  of the
speed  of administration.7--9
The  objective  of  our  study  was  to  compare  the clinical
effectiveness  of ondansetron  with  metoclopramide  in a  sin-
gle  dose  and ondansetron  in an isolated  form  in the control
of  postoperative  nausea  and  vomiting  in patients  undergoing
laparoscopic  cholecystectomy.
Methods and materials
The  current  study  included  patients  who  were  programmed
for  elective  laparoscopic  cholecystectomies  at the  surgical
ward  from  the ‘‘Dr.  José E.  Gonzalez’’  University  hospi-
tal  of  the Autonomous  University  of  Nuevo  León,  México.
The  study  consisted  of  a  comparative,  prospective,  exper-
imental,  longitudinal  double  blind  study.  Our  institution’s
Ethics  Committee  reviewed  and authorized  the  project.  The
inclusion  criteria  were  patients  undergoing  elective  laparo-
scopic  cholecystectomy,  between  18 and 60  years  old,  who
weighted  between  50  and  90  kg.  ASA I-II  patients  and both
genders  were  included.  The  exclusion  criteria  were  ASA  III-
IV  patients,  under  18  years  old,  allergic  to  the medications
included  in this study, pregnant  women,  patients  who  were
chronically  taking  prokinetics,  patients  with  an  Apfel  score
of  3--4  and  patients  who  required  any  other  medication  dur-
ing induction.  Within  exclusion  criteria  were  patients  who
presented  allergic  reactions  during  the procedure,  those
with  conversions  to  open  surgery  and  those  who  required
the  use  of  other  rescue  antiemetic  medications.
The  sample  calculation  was  performed  based on  the  arti-
cle ‘‘Risk  stratification,  nausea  and  vomiting  prophylaxis’’
postoperative,  published  by  Dr. I  Bel  Marcoval  et  al.,  in the
Spanish  magazine  of Anesthesiology  in 2006, using  the  fol-
lowing  formula,  ((2*2)/(−  +  d)2)*(Z1  −  ˛2 +  Z1  −  ˇ)2.  We
obtained  a  sample  size  of  30  patients,  via  a non-inferiority
trial  and  with  a confidence  level of  5%  (p <  0.05).  The  sample
was  divided  into  two  groups  of  15  patients  each.  Metoclo-
pramide  10  mg  and  ondansetron  4  mg  were  administered  in
the  first  Group  (A), and ondansetron  4  mg  in  the  second
Group  (B), after  induction  of  anesthesia.
The  general  objective  of  our study  was  to  compare  the
clinical  effectiveness  of  ondansetron  with  metoclopramide
in  a single  dose  and  ondansetron  in an isolated  form  in the
control  of  postoperative  nausea  and  vomiting  in patients
undergoing  laparoscopic  cholecystectomy.  Within  our  sec-
ondary  objectives  were  the application  and  comparison  of
the  Apfel  scale  for  the  risk  of  nausea  and vomiting  in the
preoperative  of  both  groups,  to  assess  the  antiemetic  effi-
cacy  of both  medications  for  their  study  groups,  and  the
requirement  of  rescue  medications.
In  the  pre-surgical  area,  demographic  data  was  col-
lected,  such  as  age,  gender  and  body mass  index  (BMI).
Their  ASA  was  determined  based on  their  pathological
and  non-pathological  background.  In  addition,  we  obtained
the signature  of  the patient  (or tutor)  for  the informed
consents.  The  patients  were  pre-medicated  with  raniti-
dine  and  midazolam,  and were  evaluated  with  the  Apfel
score.  After  the  patient  entered  the operation  room
(OR),  monitoring  and  the taking  of  basal  vital signs  were
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conducted.  Anesthetic  induction  consisted  of fentanyl
3 mcg/kg,  etomidate  0.2  mg/kg  and  atracurium  0.4  mg/kg
with  isoflurane-based  anesthetic  maintenance.  The  first
group  (A)  received  ondansetron  4  mg  and  metoclopramide
10  mg  in  a  single  dose  in  a  slow  infusion  for  20  min  after
anesthetic  induction  and  the second  group  (B)  received
ondansetron  4  mg in  the  same  fashion.  The  degree  of nau-
sea  and  vomiting  was  evaluated  with  the Likert  scale  of  5
points  (0  =  none,  1 = preview,  2 = mild,  3  =  moderate,  4 = high,
5  = intense  retching  and  presence  of vomit). Patients  were
evaluated  immediately  and  24  h  after  the postoperative
period.  Basal  time  measurements  were  conducted  4, 8, 12
and  24  h  later.
Statistical  analysis  was  performed  via  a  non-inferiority
trial;  qualitative  and  quantitative  variables  were  used.  An
alpha  value  of  0.05  was  also  used  and  null  hypothesis  was
rejected  when  the critical  value  was  under  0.05.  Nonpara-
metric  tests  were used  (x2 and parametric  (t student)).  The
electronic  data  processing  and statistical  methods  (descrip-
tive  and  inferential)  were  performed  using  STATA-IC-10-2010
software.
Results
In  the  period,  a  total  number  of 30  patients  were  obtained
and  divided  into 2  groups;  group  A (metoclopramide  and
ondansetron)  with  15  patients  and  group  B (ondansetron)
with  15  patients.
Group  A  consisted  of  2  male  patients  (13.3%),  and  13
female  (86.6%)  patients,  while  group  B consisted  of  1  male
(6.66%)  and  14  females  (93.3%).  The  difference  between  the
two  groups  was  not  statistically  significant.  Regarding  age
range,  11  patients  were  between  the ages  of  18  and  29, 8
of  them  were  between  30 and  39,  5 were  between  40 and
49  and  6  were  between  50  and 59.  Group  A consisted  of  4
patients  between  the ages  of  18  and 29,  5 between  30  and
39,  3 between  40  and  49  and 3 were  between  50  and  59.
On  the  other  hand,  Group  B consisted  of 7 patients  between
the  ages  of  18  and 29,  3 were  between  30  and  39,  2 were
between  40  and  49  and  3 were  between  50  and  59.  A statis-
tically  significant  difference  was  not  found  in the mean  age
of  the  groups.  Regarding  BMI,  8  of  the patients  who  partic-
ipated  in  the  study  had  a normal  BMI  (18.5--24.9),  15  were
overweight  (25--29.9)  and  7 had grade  I  obesity  (30--34.9).
Within  Group  A,  there  were  4  patients  with  a normal  BMI,  10
overweight  and  1  with  grade  I  obesity,  whereas  in Group  B
there  were  4  patients  with  normal  BMI,  5 overweight  and  6
with  obesity.  Once again  no  significant  differences  between
Group  A  and  Group  B were  observed.  It was  noted  that 20
of  the  patients  included  in the study  were  cataloged  as  ASA
I  and  10  as  ASA  II. No statistically  significant  difference  was
observed  in  this  parameter.
As for  the  Apfel  score,  of  the  30  patients  included  in the
study,  5 presented  1  risk  factor  out  of  the  4 of  the eval-
uation,  representing  a risk  of 20%  of  suffering  PONV.  12
patients  presented  2  factors  (a risk  of  40%);  12  patients  pre-
sented  3  factors  (a risk  of  60%)  and  1  presented  4 factors
(a  risk  of  80%).  It  was  also  noted  that  out  of  the 30  indi-
viduals  of  the study,  27  were  women, 20  were  non-smokers,
11  did  not  have  a  PONV  or  motion  sickness  background  and
postoperative  opioids  were  used in 11  patients.  The  patient
Table  2  Data  obtained  in relation  to  the  Apfel  scale.
Variable  measure  Number  of
positive  patients
Positive
variables
1  point  (20%) 5
2  points  (40%)  12
3  points  (60%)  12
4  points  (80%)  1
V. Female  27
V.  Non-smoker  20
V.  Previous  history  of
postoperative  vomiting
and/or  motion  sickness
11
V.  Use  of postoperative
opioids
11
Patient  with  vomiting  1 2
Patient  with  nausea  no.  1 1 1
Patient  with  nausea  no.  2 1 2
Patient  with  nausea  no.  3 1 3
who  presented  a vomiting  episode  had  2 positive  variables  in
the  Apfel  score,  and  the  3 subjects  of  study  who  presented
mild  nausea  had  1,  2  and 3  positive  variables  respectively
(see  Table  2).  No  statistically  significant  differences  were
observed  in this parameter  either.
Regarding  the  efficacy  of  the antiemetic  in  study,  1
patient  presented  vomiting  on a  single  occasion  immediately
after  extubation.  He  was  a  part of  Group  B (ondansetron).
2  of  the  3 patients  who  presented  nausea  (number  2  in
the  Likert  scale)  belonged  to  Group  A  (metoclopramide  and
ondansetron)  and  presented  it in  the  basal  hour  and  at  4 h.
It ceased  without  rescue  medication.  The  third  of the 3
patients  with  nausea  (number  2  in the Likert  scale)  belonged
to  Group  B (ondansetron)  and  only  presented  it during  the
basal  hour;  it  ceased  without  rescue  medication.  However,
no  differences  were  found in the severity  of  the nausea  or
the  satisfaction  of  the patients  between  groups.  Thus,  the
difference  between  both  groups  was  not  statistically  signif-
icant.
Discussion
PONV  is  among  the  most  frequent  complications  following
anesthesia  in the postoperative  of  laparoscopic  cholecystec-
tomies;  42%  of  post-operated  laparoscopic  cholecystectomy
patients  present  nausea  and  vomiting,  which  translates  into
a  greater  postoperative  discomfort  and distress  for  patients,
on  top  of  the fact that  they usually  remain  50%  longer  in the
recovery  room,  thus  altering the patient  flow  of  the  hospi-
tal  and  increasing  the internment  costs  of  each patient.  This
is  reduced  using  effective  antiemetics  in  a  single  dose  pre-
vious  to  its  presentation.  The  origin  of this  complication  is
complex  and  depends  on  a  wide  variety  of factors  previously
mentioned.
In  this  study,  the  treatment  groups  are similar  in relation
to  the  demographic  data  (inter-group  homogeneity),  surgi-
cal  procedure,  and type  of  anesthesia  and  analgesia  utilized
in  the postoperative.
The  Apfel  score  was  used  to  assess  the  risk  of presenting
PONV,  in order  to  observe  its  ability  to  forecast  this  event
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and  because  it  includes  the predisposed  factors  which  have
been  observed,  most  in different  studies,  such as  the Lenka
Doubravskaa  in 2010, which  included  1954  patients.  Here,
they  noted  the fact that being  a  woman  increased  the  risk
of  presenting  PONV,  with  an  occurrence  of  24.5%  in females
and  6.3%  in  males.  On the  other  hand,  smoking  seemed  to
be  a  protective  factor.  The  incidence  of PONV  in smokers
was  8.7%,  compared  to non-smokers,  which  was  17.7%.  Also,
a  high  PONV  incidence  was  observed  in patients  with  obe-
sity  (BMI  over 30),  at 11.8%.  In our  study,  we  were  able  to
observe  that  the 4 patients  who  did  not  present  PONV  were
all  women;  2 smokers  and  2 non-smokers;  2  with  a  PONV  or
motion  sickness  background;  and  none  were  administered
opioids  in  postoperative.  The  patient  who  presented  vomit-
ing  in  the  postoperative  had  2  positive  variables  in the Apfel
score,  and the 3  patients  who  presented  mild  nausea had
1--3  variables,  which  cast  doubt  on  the efficacy  of  the  Apfel
score  as  the  most  sensitive  PONV  predictor.10
Different  studies  have  been  conducted  around  the world,
where  different  managements  for PONV  prevention  are
proposed.  The  use  of  combined  therapies  for  a  better  mana-
gement  is  recommended  in many  of  them,  stressing  it  in
patients  with  high  risk  factors.11,12
In a  study  conducted  in Saudi  Arabia  by  Dr. Mohamed
Naguib  et  al. they included  132  patients  undergoing
laparoscopic  cholecystectomies,  who  were  randomly  admin-
istered  ondansetron  4 mg,  tropisetron  5  mg,  granisetron
3  mg,  metoclopramide  10  mg or  a  placebo  10  min  before
anesthetic  induction.  The  percentages  of patients  free  of
vomiting  were  65.5%,  52%,  48%, 29.2%  and  27.6%  in the
ondansetron,  granisetron,  tropisetron,  metoclopramide  and
placebo  groups,  respectively.  Prophylactic  antiemetic  treat-
ment  with  ondansetron  resulted  in a lower  PONV  incidence
(p  =  0.02)  than  with  metoclopramide  or  placebos.  In  our
study,  we  were  able  to  observe  that  the antiemetic  ther-
apy  with  ondansetron  with  metoclopramide  in  a single  dose
is  not  superior  to that  of  just ondansetron.13
Conclusions
Antiemetic  combined  therapy  has  proven  in some  stud-
ies  to  be  more  effective  than  monotherapy  in the  control
of  PONV.  In our  study,  a  statistically  significant  differ-
ence  was  not found  in the efficacy  of  polytherapy  with
ondansetron  with  metoclopramide  (4  mg + 10  mg)  in  a single
dose  and  monotherapy  with  ondansetron  (4  mg)  in patients
undergoing  laparoscopic  cholecystectomies  under  general
anesthesia.  However,  both  groups  of patients  presented  a
good  control  of  PONV without  the  need  for  rescue  medica-
tions.
Regarding  the Apfel  score  to  assess  the risk  of  presenting
PONV,  in  the  present  study  we  did not  find  a correlation
between  the risk  percentage  stated  by  the score  and the
patients  who  presented  PONV.
Therefore,  based on  the  results  obtained  in our  study  we
accept  the  established  hypothesis  that  the  combination  of
ondansetron  and  metoclopramide  in  a  single  dose  is as  effec-
tive  as  just  ondansetron  for  the control  of  postoperative
nausea  and  vomiting.
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